アンチセンスとRNAi治療薬市場の成長と動向
Grand View Research, Inc.の最新レポートによると、アンチセンス&RNAi治療薬の世界市場規模は、2024年から2030年にかけて18.12%のCAGRを記録し、2030年までに146億6000万米ドルに達すると予測されている。生物学的ベクターやナ…
Liver Cancer Drug Market Size, Share & Trends Analysis Report By Drug Class (Targeted Therapy, Immunotherapy, Chemotherapy), By Region, And Segment Forecasts, 2023 - 2030
RNA Therapeutics Market by Product (Vaccines, Drugs), Type (mRNA Therapeutics, RNA Interference, Antisense Oligonucleotides), Indication (Infectious Diseases, Rare Genetic Diseases), End User (Hospitals & Clinics) - Global Forecast to 2028
The Next Generation Drug Conjugates Market: Focus on GalNac Conjugate, Peptide Drug Conjugate, Peptide Oligonucleotide Conjugate, RNAi Conjugate, Peptide Receptor Radionuclide Therapy, Small Molecule-Drug Conjugate (SMDC), and Other Conjugates Distribution by Type of Targeting Ligand (Amino Sugar, Lipid, Peptide, Small Molecule and Virus-like Particles), Type of Payload (Peptide, Small Molecule, Oligonucleotide and Radionuclide), Type of Therapy (Monotherapy and Combination Therapy), Route of Administration (Intravenous, Subcutaneous and Others), Mechanism of Action (sequence-specific target binding, radiation induced cytotoxicity, cancer-specific surface target mediated cytotoxicity, drug induced cytotoxicity, receptor mediated internalization and cytotoxicity and others) and Key Target Indications (Gastroenteropancreatic Neuroendocrine Tumors, Prostate Cancer, Leptomeningeal Carcinomatosis caused by Breast Cancer Brain Metastases, Hereditary Transthyretin Amyloidosis, Atherosclerotic Cardiovascular Diseases, Severe Hypertriglyceridemia, Hereditary Angioedema, Acute Hepatic Porphyria, Primary Hyperoxaluria, Heterozygous Familial Hypercholesterolemia, Hemophilia, Low-Risk Myelodysplastic Syndrome, Myelofibrosis, Alpha-1 Antitrypsin Deficiency Liver Disease and Familial Chylomicronemia Syndrome) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035
Intro on Nucleic Acid Therapeutics CDMO
The global nucleic acid therapeutics CDMO market was valued at $3.88 billion in 2022 and is expected to reach $14.19 billion by 2033, growing at a CAGR of 12.55% during the forecast period 2023-2033. The key factor…
Non-Viral Drug Delivery Systems Market (2nd Edition), 2023-2035: Distribution by Type of Molecule Delivered (Small Molecules and Biologics), Type of Biologic Delivered (RNAi / mRNA, DNA Oligonucleotides, Antibodies, Proteins / Peptides), Type of Vehicle Used (Cell Penetrating Peptides, Extracellular Vesicles, Oligonucleotides, Nanoparticles and Polymers), Target Therapeutic Area (Infectious Diseases, Oncological Disorders, Genetic Disorders, Neurological Disorders, Hepatic Disorders, Cardiovascular Disorders and Other Disorders), Type of Payment (Upfront Payments and Milestone Payments) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2023-2035
Exosome Therapy Market, Distribution by Type of Therapeutic (Allogeneic and Autologous), Target Indication (Degenerative Meniscal Injury, Dystrophic Epidermolysis Bullosa, Fistula Perianal and Retinitis Pigmentosa), Therapeutic Area (Dermatological Disorders, Musculoskeletal Disorders, Ophthalmic Diseases and Rectal Disorders), Route of Administration (Fistula Tract, Intra-articular and Intra-ocular) and Geography (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2040